Latest News - Boston Scientific
Top Corporates Hub
Boston Scientific
Is It Time To Revisit Boston Scientific (BSX) After This Year’s Sharp Share Price Pullback
08.04.2026 03:11
Investors may be wondering if Boston Scientific at around US$61.86 is starting to look attractive, or if the recent pullback is hinting at deeper valuation questions. The stock is down about 1.4% over the last week, 13.3% over the last month, and 34.7% year to date, with a 31.8% decline over 1 year, while the 3 and 5 year returns sit at 21.9% and 57.0% respectively. These moves are set against a backdrop of ongoing attention on Boston Scientific's role in the medical device space and how...
Boston Scientific Corp (NYSE:BSX) Offers Affordable Growth for Value-Conscious Investors
07.04.2026 08:11
Boston Scientific (BSX) exemplifies affordable growth investing, offering strong double-digit expansion at a reasonable valuation backed by high profitability.
Boston Scientific's 2026 Guidance 'Reasonable', RBC Says
02.04.2026 14:57
Boston Scientific's (BSX) 2026 guidance is "reasonable", but stock sentiment is being driven by the
Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
01.04.2026 11:40
Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best 52-Week Low NYSE Stocks to Buy Now. On March 29, 2026, Boston Scientific Corporation (NYSE:BSX) announced that its CHAMPION-AF clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device versus NOACs for stroke risk reduction in patients […]
Boston Scientific: From Hypergrowth To Durable Compounding
01.04.2026 04:43
Boston Scientific (BSX) is down 35% but still growing fast with strong marginsâsee valuation, key catalysts (WATCHMAN, EP, M&A), and risks.
Boston Scientific (BSX) Stock Trades Down, Here Is Why
31.03.2026 02:06
Shares of medical device company Boston Scientific (NYSE:BSX) fell 9.4% in the afternoon session after Raymond James downgraded the stock to Outperform from Strong Buy, citing worries about the company's growth prospects. The firm lowered its price target and estimates to reflect slower trends in Boston Scientific's key growth areas, specifically U.S. electrophysiology and its Watchman device.
Boston Scientific Corporation (BSX) Presents at American College of Cardiology 75th Annual Scientific Session and Expo - Slideshow
29.03.2026 13:00
2026-03-29. The following slide deck was published by Boston Scientific Corporation in conjunction with this event.
Boston Scientific Corporation (BSX) Presents at American College of Cardiology 75th Annual Scientific Session and Expo Transcript
29.03.2026 00:45
Boston Scientific Corporation (BSX) American College of Cardiology 75th Annual Scientific Session and Expo March 28, 2026 6:30 PM EDTCompany...
Boston Scientific Unveils “Practice-Transforming” Trial Data for PE and AF at ACC Conference Call
29.03.2026 00:04
Boston Scientific (NYSE:BSX) executives highlighted new data from two randomized clinical trials during an American College of Cardiology conference call, describing the results as potentially “practice transforming” for pulmonary embolism (PE) and stroke prevention in atrial fibrillation (AF). The
What Moved Markets This Week
28.03.2026 06:44
U.S. stocks ended lower on the week as elevated U.S.-Iran tensions remained in focus. Read more about this week's major events on Wall Street.
Why The Narrative Around Boston Scientific (BSX) Is Shifting As Analysts Reset Expectations
26.03.2026 10:03
Boston Scientific’s fair value estimate has been adjusted from US$104.24 to US$102.00, a modest trim that lines up with the recent wave of price target resets across the Street. Analysts are not making sweeping calls on the business model; instead, they are tightening their assumptions on growth and execution, which feeds directly into where those targets land. As you read on, you will see how these shifting targets and research themes can help you track the evolving story around the...
Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
25.03.2026 02:50
Amidst the ongoing pressure, we are now upgrading Boston Scientific stock from hold to buy. Click here to read why.
Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
22.03.2026 03:09
If you are wondering whether Boston Scientific's current share price still reflects its long term potential, the recent moves in the stock give you plenty to think about. The shares last closed at US$69.48, with returns of 0.5% over 7 days, a 6.8% decline over 30 days, a 26.6% decline year to date, and a 31.0% decline over 1 year, set against gains of 44.1% over 3 years and 81.8% over 5 years. These mixed returns have kept attention on how the market is weighing Boston Scientific's growth...
Truist Cuts PT on Boston Scientific Corporation (BSX) to $92 From $95 – Here’s Why
21.03.2026 10:29
Boston Scientific Corporation (NYSE:BSX) is one of the best long term stocks to invest in according to billionaires. Truist cut the price target on Boston Scientific Corporation (NYSE:BSX) to $92 from $95 on March 18, reiterating a Buy rating on the shares. The rating update came ahead of the company’s CHAMPION-AF readout, with the firm […]
Needham Reiterates Buy on Boston Scientific, Maintains $97 Price Target
20.03.2026 06:25
Needham analyst Mike Matson reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $97 price target.
Sacral neuromodulation: broadening Boston Scientific’s European urology portfolio
18.03.2026 12:39
Boston Scientific added SNM to its urology portfolio following its 2024 acquisition of Axonics.
PFA startup Field Medical appoints Mark Turco as CEO
18.03.2026 11:13
Turco, an interventional cardiologist, has held roles including CEO of JC Medical and chief medical officer of Medtronic’s aortic and peripheral vascular business.
Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
16.03.2026 11:07
Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX) over disclosures about its U.S. Electrophysiology segment. Plaintiffs allege the company misled investors about growth prospects and competitive threats in this business line. The lawsuits follow disappointing financial results and guidance that highlighted pressures in Electrophysiology. Legal claims focus on supposed misrepresentations by company leadership regarding business fundamentals and...
Assessing Boston Scientific (BSX) Valuation After Recent Penumbra Acquisition And Share Price Weakness
14.03.2026 17:08
Why Boston Scientific is on investors’ radar today Boston Scientific (BSX) sits at the center of the medical devices story, and its stock performance over the past year gives investors a clear snapshot of how the market currently values that position. See our latest analysis for Boston Scientific. At a share price of US$69.13, Boston Scientific’s recent move includes a 1-day share price return of 0.85% and a 90-day share price return decline of 25.33%, while the 5-year total shareholder...